The determination of carcinoembryonic antigen (CEA) in plasma has been of much interest currently concomitant with the search for an immunologic diagnosis test. Recent reports have shed some doubt on the specificity of carcinoembryonic antigens for gastrointestinal tract malignancies. This report details the plasma CEA values in 341 patients with varying gynecologic malignancies. These studies have demonstrated that plasma CEA is elevated in close to 50 per cent of patients with invasive gynecologic cancer. The incidence of positive values is appreciably higher in the advanced stages of disease. Of particular interest was that 84 per cent (21 of 25) of the patients with recurrent squamous-cell carcinoma of the cervix had a positive CEA value. Similar results were found in patients with cancer of the vulva, ovary, and endometrium.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0002-9378(75)90631-6 | DOI Listing |
J Anus Rectum Colon
January 2025
Department of Coloproctological Surgery, Juntendo University Faculty of Medicine, Tokyo, Japan.
Objectives: This study was conducted to investigate whether preoperative or postoperative carcinoembryonic antigen (CEA) with a new cut-off value is more optimal for predicting long-term outcomes in patients with Stage II/III rectal cancer, and to investigate the effectiveness of postoperative adjuvant chemotherapy (POAC) based on the CEA values.
Methods: Serum CEA levels were measured preoperatively (pre-CEA) and postoperatively (post-CEA). The area under the receiver operating curve (AUROC) was used to determine a cut-off for CEA.
Cureus
December 2024
General Surgery, Corewell Health Dearborn Hospital, Dearborn, USA.
Introduction Colorectal cancer (CRC) is among the most frequent cancers in the United States. There are recognized guidelines for monitoring after curative CRC excision. This study looks into the rate of compliance with surveillance guidelines following CRC resection, as well as the impact of demographic characteristics.
View Article and Find Full Text PDFMikrochim Acta
January 2025
Department of Chemistry and Center of Excellence for Innovation in Chemistry, Faculty of Science, Ubon Ratchathani University, Ubon Ratchathani, 34190, Thailand.
Carcinoembryonic antigen (CEA) and C-reactive protein (CRP) are biomacromolecules known as cancer and inflammatory markers. Thus, they play a crucial role in early cancer diagnosis, post-treatment recurrence detection, and tumor risk assessment. This paper describes the development of an ultrasensitive and selective imprinted paper-based analytical device (PAD) as impedance sensor for determination of CEA and CRP in serum samples for point-of-care testing (POCT).
View Article and Find Full Text PDFSurgery
January 2025
Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan. Electronic address:
Background: A positive pathologic retroperitoneal surgical resection margin in the retroperitonealized colon is reported to predict distant metastases. However, no studies have investigated retroperitoneal surgical resection margin positivity on computed tomography colonography and its prognostic significance.
Methods: Patients who underwent primary resection for ascending or descending colon cancer at our institution between 2013 and 2018 were retrospectively evaluated (n = 206).
Asian Pac J Cancer Prev
January 2025
Department of Nuclear Medicine, Busan Paik Hospital, University of Inje College of Medicine, Busan, Republic of Korea.
Objective: This study aimed to develop a simple machine-learning model incorporating lymph node metastasis status with F-18 Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) and clinical information for predicting regional lymph node metastasis in patients with colon cancer.
Methods: This retrospective study included 193 patients diagnosed with colon cancer between January 2014 and December 2017. All patients underwent F-18 FDG PET/CT and blood test before surgery.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!